Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DKY709

Small molecule (Molecular glue degrader) · Degrader of IKZF2 (Helios) (IKZF2) · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer

What is DKY709?

DKY709 is a low molecular weight degrader of IKZF2 (Helios), a zinc finger transcription factor expressed on most regulatory T-cells. It binds the E3 ubiquitin ligase substrate receptor and brings IKZF2 to it for ubiquitination and proteasomal degradation, which can activate T-lymphocytes. It is being studied in non-small-cell lung carcinoma, melanoma, nasopharyngeal carcinoma, microsatellite stable colorectal cancer, and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule (Molecular glue degrader)
Targets
IKZF2 (Helios) (IKZF2)
Mechanism
Degrader of IKZF2 (Helios) (IKZF2)
Pathways
E3 ubiquitin ligase-mediated ubiquitination, proteasome-mediated degradation, T-cell activation, regulatory T-cell immunosuppression
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Carcinoma, Non-Small-Cell LungMelanomaMicrosatellite Stable Colorectal CancerNasopharyngeal CarcinomaTriple Negative Breast Cancer

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind DKY709

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.